Biotimize

About Biotimize

Positioned as a pivotal player in the South American biotechnology sector, Biotimize operates as Brazil's first Contract Development and Manufacturing Organization (CDMO) focused on biologics. The company was founded in 2016 by Fernando Cesar Barbosa and Talison Chaves Lucas to address a significant gap in the local market, where the absence of a domestic biological CDMO created substantial hurdles for universities, startups, and pharmaceutical companies in developing biological Active Pharmaceutical Ingredients (APIs). This dependency on international services resulted in increased bureaucracy, costs, and timelines, often preventing promising research from advancing.

Biotimize's business model is structured as Biotechnology as a Service (BaaS), providing personalized, non-GMP (Good Manufacturing Practice) services for the development of biopharmaceuticals. The company serves a diverse client base, including global companies, research institutions, and the public sector, by offering a comprehensive suite of services. These services cover the full spectrum of early-stage development, from cell line development and process optimization to producing preclinical materials and technical-economic analysis. By localizing these capabilities, Biotimize aims to reduce development costs by up to 50% and significantly shorten production timelines for its partners.

A significant milestone for the company was the April 2024 inauguration of its first service laboratory in Piracicaba, São Paulo, which operates under Good Laboratory Practices (GLP) and is equipped for biosafety levels 1 and 2. This facility is engineered to develop vaccines and biologics from living cells, including bacteria, yeast, mammalian cells, and viruses. Looking ahead, Biotimize is expanding its infrastructure with the construction of a new GMP-compliant production platform and R&D center on a 20,000 m² plot of land donated by the City of Piracicaba. In September 2022, the company announced a $30 million Series A fundraising round to finance this expansion, which will feature single-use technologies for producing clinical and commercial batches of recombinant proteins, positioning it as the only end-to-end CDMO solution in South America.